Indication

Limb-Girdle Muscular Dystrophy Type 2I

1 clinical trial

1 product

Clinical trial

A Phase 3 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)

Status: Recruiting, Estimated PCD: 2027-07-01

Product